# The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

> **NCT00421733** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 281 (actual)

## Conditions studied

- Diabetic Nephropathy
- Chronic Kidney Disease

## Interventions

- **DRUG:** Zemplar (paricalcitol ) capsules
- **DRUG:** Zemplar (paricalcitol) capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00421733
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421733, "The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00421733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*